N-Acetyl-Cysteine for Treatment of AGA in Men

• Status: Recruiting
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

To study the effectiveness and safety of the reactive oxygen species scavenger N-acetyl-cysteine (NAC) as a single therapy and in combination with the topically applied minoxidil for the treatment of the early-onset androgenetic alopecia in men.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kafrelsheikh University
• Collaborator: Ain Shams University
• Treatments: Acetylcysteine; Minoxidil; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Male patients between 18-30 years old affected by mild to moderate AGA up to grade IV on the Norwood-Hamilton scale.

Exclusion Criteria:

• Patients with contraindication to intake of NAC like patients on nitrates.

• Patients with AGA who were on systemic treatment (Finasteride, Dutasteride) in the previous 12 months.

• Patients with AGA who received topical treatment for AGA in the last 6 months.

• Patients with AGA taking any antioxidants, food and vitamin supplements within the last 3 months.

• Patients with pathological systemic diseases or environmental factors which provide a high oxidative stress state including heavy smoking, alcohol consumption, diagnosis of metabolic syndrome, and prolonged exposure to ultraviolet.